Precision BioSciences
American biotechnology company
Precision BioSciences is a biotechnology company based in the United States that focuses on the development of genome editing technologies. The company is known for its proprietary ARCUS genome editing platform, which is derived from a natural genome editing enzyme called I-CreI. Precision BioSciences aims to apply its technology to various fields, including gene therapy, agriculture, and biopharmaceuticals.
History[edit]
Precision BioSciences was founded in 2006 by a group of scientists from Duke University, including Matthew Kane, Derek Jantz, and Jeffrey Smith. The company was established to commercialize the ARCUS genome editing technology, which was developed based on the research conducted at Duke University. Over the years, Precision BioSciences has expanded its operations and formed partnerships with various organizations to advance its research and development efforts.
Technology[edit]
The core technology of Precision BioSciences is the ARCUS genome editing platform. ARCUS is based on a naturally occurring enzyme, I-CreI, which is a type of meganuclease. This enzyme has been engineered to create highly specific double-strand breaks in DNA, allowing for precise editing of the genome. The ARCUS platform is designed to be more specific and efficient than other genome editing technologies, such as CRISPR-Cas9.
Applications[edit]
Precision BioSciences is applying its ARCUS technology in several key areas:
- Gene Therapy: The company is developing gene therapies for various genetic disorders. By using ARCUS to precisely edit genes, Precision BioSciences aims to correct genetic mutations that cause diseases.
- Agriculture: In the agricultural sector, Precision BioSciences is working on developing crops with improved traits, such as increased yield, disease resistance, and enhanced nutritional content.
- Biopharmaceuticals: The company is also exploring the use of ARCUS in the development of biopharmaceuticals, including the production of therapeutic proteins and antibodies.
Partnerships and Collaborations[edit]
Precision BioSciences has established several partnerships to advance its research and development efforts. These collaborations include partnerships with academic institutions, research organizations, and other biotechnology companies. Through these partnerships, Precision BioSciences aims to leverage external expertise and resources to accelerate the development of its genome editing technologies.
Related pages[edit]
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
